1469338-58-6

Basic information

• Product Name: (1S,2S,3R,4R)-methyl-3-((S)-1-acetamido-2-ethylbutyl)-4-(2,3-bis(tert-butoxycarbonyl)guanidino)-2-(((3-(((E)-3-(3,4-bis(allyloxy)phenyl)acryloyl)oxy)propyl)carbamoyl)oxy)cyclopentanecarboxylate
• Synonyms: (1S,2S,3R,4R)-methyl-3-((S)-1-acetamido-2-ethylbutyl)-4-(2,3-bis(tert-butoxycarbonyl)guanidino)-2-(((3-(((E)-3-(3,4-bis(allyloxy)phenyl)acryloyl)oxy)propyl)carbamoyl)oxy)cyclopentanecarboxylate
• CAS NO: 1469338-58-6
• Molecular Weight: 886.053
• Mol File: 1469338-58-6.mol
• Article Data: 1

Chemical Properties

• CAS DataBase Reference: (1S,2S,3R,4R)-methyl-3-((S)-1-acetamido-2-ethylbutyl)-4-(2,3-bis(tert-butoxycarbonyl)guanidino)-2-(((3-(((E)-3-(3,4-bis(allyloxy)phenyl)acryloyl)oxy)propyl)carbamoyl)oxy)cyclopentanecarboxylate(CAS DataBase Reference)
• NIST Chemistry Reference: (1S,2S,3R,4R)-methyl-3-((S)-1-acetamido-2-ethylbutyl)-4-(2,3-bis(tert-butoxycarbonyl)guanidino)-2-(((3-(((E)-3-(3,4-bis(allyloxy)phenyl)acryloyl)oxy)propyl)carbamoyl)oxy)cyclopentanecarboxylate(1469338-58-6)
• EPA Substance Registry System: (1S,2S,3R,4R)-methyl-3-((S)-1-acetamido-2-ethylbutyl)-4-(2,3-bis(tert-butoxycarbonyl)guanidino)-2-(((3-(((E)-3-(3,4-bis(allyloxy)phenyl)acryloyl)oxy)propyl)carbamoyl)oxy)cyclopentanecarboxylate(1469338-58-6)

Safety Data

• Hazardous Substances Data: 1469338-58-6(Hazardous Substances Data)

Upstream product

• 229613-83-6 (–)-methyl (1S,4R)-4-aminocyclopent-2-ene-1-carboxylate hydrochloride 
• 168683-02-1 (1S,4R)-(-)-methyl-[[(1,1-dimethylethoxy)carbonyl]amino]cyclopent-2-ene-1-carboxylate 
• 229613-93-8 (+)-methyl (3aR,4R,6S,6aS)-4-[(tert-butoxycarbonyl)-amino]-3-(1-ethylpropyl)-4,5,6,6a-tetrahydro-3aH-cyclopenta[d]isoxazole-6-carboxylate 
• 322474-21-5 N,N'-bis-Boc-S-methyl-isothiourea 
• 383910-26-7 (-)-methyl (1S,2S,3R,4R)-3-[(1S)-1-(acetylamino)-2-ethylbutyl]-4-({[(tert-butoxycarbonyl)amino][(tert-butoxycarbonyl)imino]methyl}amino)-2-hydroxycyclopentanecarboxylate 
• 229614-17-9 (-)-methyl (1S,2S,3R,4R)-3-[(1S)-1-(acetylamino)-2-ethylbutyl]-4-amino-2-hydroxycyclopentanecarboxylate hydrochloride 

Relevant articles and documents

ENHANCED ANTI-INFLUENZA AGENTS CONJUGATED WITH ANTI-INFLAMMATORY ACTIVITY

Novel dual-targeted, bifunctional anti-influenza drugs formed by conjugation with anti-inflammatory agents are disclosed. Exemplary drugs according to the invention include caffeic acid (CA)-bearing zanamivir (ZA) conjugates ZA-7-CA (1), ZA-7-CA-amide (7) and ZA-7-Nap (43) for simultaneous inhibition of influenza virus neuraminidase and suppression of proinflammatory cytokines. Synthetic methods for preparation of these enhanced anti-influenza conjugate drugs are provided. The synthetic bifunctional ZA conjugates act synergistically towards protection of mice lethally infected by H1N1 or H5N1 influenza viruses. The efficacy of ZA-7-CA, ZA-7-CA-amide and ZA-7-Nap conjugates is much greater than the combination therapy of ZA with anti-inflammatory agents.